摘要目的:分析维思通与思瑞康治疗对住院男性精神分裂症患者增重、内分泌和体内代谢的影响。方法:选取2016年8月至2018年8月在本院接受治疗的126例男性精神分裂症患者为研究对象,随机分为维思通组及思瑞康组,63例/组。对比两组治疗疗效,比较两组患者治疗前后体质量、空腹血糖(FPG)、血脂[总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白(HDL)和低密度脂蛋白(LDL)]及内分泌激素[催乳素(PRL)、睾酮、游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)]变化情况。统计两组患者治疗期间不良反应发生情况。结果:维思通组及思瑞康组治疗有效率无明显差异(87.30% vs 88.89%,P>0.05)。治疗后,维思通组BMI、FPG,TC、TG、HDL、LDL、睾酮、FT3及 FT4水平均与治疗前无明显差异(P>0.05);思瑞康组FPG、HDL、LDL、PRL、睾酮、FT3及 FT4水平与治疗前无明显差异(P>0.05)。维思通组治疗后PRL水平高于治疗前及思瑞康组(P<0.05);思瑞康组治疗后BMI及TC、TG水平高于治疗前及维思通组(P<0.05)。维思通组不良反应发生率明显高于思瑞康组(61.90% vs 33.33%,P<0.05)。结论:维思通与思瑞康对男性精神分裂症的疗效相当,但思瑞康对椎体反应及内分泌的影响更小,且对性功能的影响低,增加了男性患者的治疗依从性。
Abstract：Objective: To analyze the effects of wisconsin and Siruikang treatment on weight gain, endocrine and metabolism in hospitalized male patients with schizophrenia. Methods: A total of 126 male schizophrenia patients who were treated in the hospital from Aug. 2016 to Aug. 2018 were enrolled in the study. They were randomly divided into wisconsin group and the Siruikang group, 63 cases in each group. The curative effect, changes in body mass, fasting plasma glucose (FPG), blood lipids [total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) ], endocrine hormones [prolactin (PRL), testosterone, free triiodothyronine (FT3), free thyroxine (FT4) ] before and after treatment were compared between the two groups. The occurrence of adverse reactions during treatment in both groups was statistically analyzed. Results: There was no significant difference in the effective rate of treatment between the wisconsin group and the Siruikang group (87.30% vs 88.89%, P>0.05). There was no significant difference in BMI, FPG, TC, TG, HDL, LDL, testosterone, FT3 or FT4 level in Siruikang group before and after treatment (P>0.05). There was no significant difference in FPG, HDL, LDL, PRL, testosterone, FT3 or FT4 level in wisconsin group before and after treatment (P>0.05). After treatment, level of PRL in Siruikang group was higher than that before treatment and that in wisconsin group (P<0.05). After treatment, levels of BMI, TC and TG in wisconsin group were higher than those before treatment and those in Siruikang group (P<0.05). The incidence of adverse reactions in siruikang group was significantly higher than that in wisconsin group (61.90% vs 33.33%, P<0.05). Conclusion: The curative effect of wisconsin and Siruikang is comparable on male schizophrenia patients. However, the effects of Siruikang are less on vertebral reaction and endocrine, with lower effects on sexual function, which increases treatment compliance of male patients.
熊倩, 余建英, 严凯, 徐小凤, 宋锦平. 维思通与思瑞康治疗对住院男性精神分裂症患者增重内分泌和体内代谢的影响[J]. 河北医学, 2020, 26(3): 370-373.
XIONG Qian, YU Jianying, YAN Kai, et al. Effects of Wisconsin and Siruikang on Weight Gain Endocrine and Metabolism in Hospitalized Male Patients with Schizophrenia. HeBei Med, 2020, 26(3): 370-373.
[1] Macdonald S,Halliday J,MacEWAN T,et al.Nithsdale Schizophrenia Surveys 24:sexual dysfunction.Case-control study.[J].Br Psychiatry,2018,182(1):50~56. [2] Keefe R S,Kahn R S.Cognitive decline and disrupted cognitive trajectory in schizophrenia[J].Jama Psychiatry,2017,74(5):535~536. [3] 周进涛,崔中芹,刘燕朋,等.二甲双胍缓释片治疗非典型抗精神病药致精神分裂症糖脂代谢紊乱的临床研究[J].川北医学院学报,2016,31(1):55~57. [4] 刘连忠,张娟,吕路,等.利培酮、喹硫平、齐拉西酮对首发女性精神分裂症患者妊娠的影响[J].基因组学与应用生物学,2017,36(4):1403~1409. [5] 陈强,周芳珍,农玉贤.奎硫平联合齐拉西酮或氯氮平治疗难治性精神分裂症的临床观察[J].临床精神医学杂志,2016,26(1):53. [6] 安培玉,孙杰峰,段惠峰,等.奥氮平与氟哌啶醇改善老年精神分裂症精神症状及认知功能的差异性研究[J].华南国防医学杂志,2017,31(11):723~725. [7] 侯云跃,范林钰,刘茂航.利培酮、喹硫平单用和分别联合盐酸舍曲林治疗精神分裂症的临床对比研究[J].广西医科大学学报,2016,33(6):985~988. [8] Rojo L E,Gaspar P A,Silva H,et al.Metabolic syndrome and obesity among users of second generation antipsychotics:a global challenge for modern psychopharmacology[J].Pharmacological Research,2015,101(26):74~85. [9] 陈勤,杨栋,邓丽俐,等.抗精神病药物对精神分裂症患者血清泌乳素影响的研究[J].精神医学杂志,2017,30(5):340~342.
2020, Vol. 26 
冀公网安备13080202000786号